<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718328</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00016284</org_study_id>
    <secondary_id>NIH UL1 RR 025005</secondary_id>
    <nct_id>NCT00718328</nct_id>
  </id_info>
  <brief_title>Simvastatin For Intracerebral Hemorrhage Study</brief_title>
  <official_title>Simvastatin For Intracerebral Hemorrhage Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective: To analyze if statins are effective in ameliorating perihematomal edema
      evolution thereby reducing mortality and improving functional outcomes following spontaneous
      intracerebral hemorrhage (ICH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intracerebral hemorrhage (ICH) causes 10% to 15% of first-ever strokes, with a 30-day
      mortality rate of 35% to 52% with only 20% expected to be functionally independent at 6
      months. No medical or surgical interventions have been found to alter the natural evolution
      of this disease. The high risk for mortality and poor outcomes seems to occur despite
      relatively small hematoma volumes and small amounts of neuronal tissue at risk for injury.
      The reasons for this observation remain unknown; however perihematomal edema formation and
      inflammation that follows ICH seems to play an important role.

      The Simvastatin for Intracerebral Hemorrhage Study is a prospective double blinded placebo
      controlled randomized (1:1) clinical trial that compares outcomes in patients receiving
      generic simvastatin 80 mg for 14 days or until death or discharge with patients in the
      placebo group.

      The hypothesis for our study is that statins ameliorate perihematomal edema evolution thereby
      reducing mortality and improving functional outcomes following Intracerebral Hemorrhage
      (ICH). This hypothesis in turn is based on animal data showing suppression of inflammatory
      reaction and improved neurological outcomes following administration of statins to rodents
      with experimental ICH, and on a retrospective review of patients admitted to The Johns
      Hopkins Hospital over the last 7 years with spontaneous ICH which showed significantly better
      outcomes (decreased 30 day mortality secondary to decreased perihematomal edema) in patients
      on statins at the time of admission.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment, trial terminated
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perihematomal Edema</measure>
    <time_frame>Days 7 and 14</time_frame>
    <description>Solitary patient lost to follow up (out of state)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 80 mg</intervention_name>
    <description>Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with CT evidence of ICH admitted within 24 hours of onset of symptoms.

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 85

          -  Admission Glasgow Coma Score (GCS) &lt; 6

          -  ICH volume &lt; 10 cc

          -  ICH secondary to trauma, aneurysm, Arterio-Venous Malformation (AVM), tumor or post
             surgical

          -  Multiple ICH

          -  Associated Subdural hematoma or significant Subarachnoid hemorrhage

          -  History of prior neurologic disease with modified Rankin Scale (mRS) &gt; 1

          -  Hematoma evacuation, hemicraniectomy, clot lysis

          -  Myopathy

          -  Active Liver disease

          -  Pregnancy

          -  Statin allergy

          -  Patients on statins prior to admission

          -  Patients with an acute indication for statin therapy (Unstable angina)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeraj S Naval, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008;8(1):6-12.</citation>
    <PMID>17701108</PMID>
  </reference>
  <reference>
    <citation>Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Carhuapoma JR. An association of prior statin use with decreased perihematomal edema. Neurocrit Care. 2008;8(1):13-8.</citation>
    <PMID>17701107</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <results_first_submitted>May 7, 2017</results_first_submitted>
  <results_first_submitted_qc>May 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2017</results_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracerebral</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Edema</keyword>
  <keyword>Statins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period October 2008- June 2009, Inpatient (ICU)</recruitment_details>
      <pre_assignment_details>No issues prior to assignment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin Group</title>
          <description>Simvastatin 80 mg: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Prematurely terminated due to poor enrollment</participants>
                <participants group_id="P2" count="0">Terminated due to poor enrollment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin Group</title>
          <description>Simvastatin 80 mg: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="62" upper_limit="62"/>
                    <measurement group_id="B3" value="62" lower_limit="62" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Perihematomal Edema</title>
        <description>Solitary patient lost to follow up (out of state)</description>
        <time_frame>Days 7 and 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin Group</title>
            <description>Simvastatin 80 mg: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.</description>
          </group>
        </group_list>
        <measure>
          <title>Perihematomal Edema</title>
          <description>Solitary patient lost to follow up (out of state)</description>
          <units>Relative perihematomal edema</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patient lost to follow up</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Simvastatin Group</title>
          <description>Simvastatin 80 mg: Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo: Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neeraj Naval</name_or_title>
      <organization>Johns Hopkins University SOM (former employer during the study)</organization>
      <phone>9042026290</phone>
      <email>neerajnaval@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

